Episode Details

Summary

Hosts Sapna Patel and James Larkin discuss what they're currently watching on tv & streaming services. (Spoiler: Eric Cartman on Ozempic)

The main conversation delves into the Relativity 48 study of triple immune checkpoint inhibition presented at ASCO 2024. The hosts discuss the study's design, patient characteristics, safety profile, and efficacy results, highlighting the importance of understanding the implications of this new treatment regimen. They also explore future directions for research and the potential impact on clinical practice.

Keywords

Relativity 48, melanoma, triple therapy, immune checkpoint inhibitors, safety, efficacy, ASCO 2024

Takeaways

• The Relativity 48 study is a significant advancement in melanoma treatment.
• Triple therapy includes nivolumab, rlatlimab, and ipilimumab.
• Safety profile shows 100% of patients experienced adverse events.
• Median PFS has not been reached, indicating ongoing efficacy evaluation.
• The objective response rate was reported at 59%.
• Patient selection may introduce bias in treatment outcomes.
• Future studies are needed to confirm safety and efficacy in broader populations.
• LAG3 blockade's dose responsiveness remains an open question.
• Community oncologists are sensitive to toxicity issues in treatment.
• The study has not yet been published, awaiting further analysis.

Titles

Relativity 48: What We Learned from ASCO 2024

Triple Therapy for Melanoma: Safety and Efficacy Insights

Sound Bites

"100% of patients had an adverse event."

"Median PFS has not been reached yet."

"The objective response rate was 59%."

Chapters

00:00 Introduction and TV Preferences

02:55 Overview of the Relativity 48 Study

09:20 Safety Profile of the Triple Therapy

15:39 Objective Response Rate and Independent Central Review

18:23 Progression-Free Survival and Follow-Up

24:00 Exploring Higher Doses of Ipilimumab and Future Trials

31:45 Fact Check